Janssens Sandrien, de Armas Hector Novoa, D'Autry Ward, Van Schepdael Ann, Van den Mooter Guy
Laboratorium voor Farmacotechnologie en Biofarmacie, Katholieke Universiteit Leuven, Leuven, Belgium.
Eur J Pharm Biopharm. 2008 Aug;69(3):1114-20. doi: 10.1016/j.ejpb.2008.02.007. Epub 2008 Feb 16.
The good compatibility between Itraconazole and polyvidone-vinylacetate 64 (PVPVA 64) was pointed out previously. However, the dissolution properties of these systems left room for improvement. Therefore polyethylene glycol 6000 (PEG 6000), known for its solubilizing and wetting properties, was added to the PVPVA 64 matrix. Physicochemical analysis showed that up to 10% of PEG 6000 could be mixed with PVPVA 64. Addition of 10%, 20% or 40% of Itraconazole rendered amorphous solid dispersions consisting of a ternary mixed phase and a PVPVA 64 rich amorphous phase. If the PEG 6000 fraction was elevated up to 25% of the carrier, the PEG 6000 crystallinity degree was around 73+/-0.6%. Up to 20% of Itraconazole could be molecularly dispersed in the 25/75 w/w polymer blend. An Itraconazole melting peak could be detected for the sample containing 40% of drug. Dissolution experiments showed that no benefit was obtained by adding PEG 6000 to the PVPVA 64 matrix for samples containing up to 20% of Itraconazole. The dissolution of the ternary dispersions with 40% of Itraconazole on the other hand showed improvement compared to binary Itraconazole/PVPVA 64 dispersions.
先前已指出伊曲康唑与聚维酮 - 醋酸乙烯酯64(PVPVA 64)具有良好的相容性。然而,这些体系的溶解性能仍有改进空间。因此,将以增溶和润湿性著称的聚乙二醇6000(PEG 6000)添加到PVPVA 64基质中。物理化学分析表明,PEG 6000与PVPVA 64的混合比例最高可达10%。添加10%、20%或40%的伊曲康唑可形成由三元混合相和富含PVPVA 64的非晶相组成的非晶态固体分散体。如果PEG 6000的比例提高到载体的25%,PEG 6000的结晶度约为73±0.6%。高达20%的伊曲康唑可分子分散在25/75 w/w的聚合物共混物中。对于含有40%药物的样品,可以检测到伊曲康唑的熔融峰。溶出实验表明,对于含有高达20%伊曲康唑的样品,向PVPVA 64基质中添加PEG 6000并无益处。另一方面,与二元伊曲康唑/PVPVA 64分散体相比,含有40%伊曲康唑的三元分散体的溶出度有所提高。